n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide has been researched along with Adenocarcinoma in 33 studies
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide: structure given in first source
NS-398 : A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2.
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gemcitabine is a chemotherapeutic drug widely used in the treatment of non-small cell lung carcinoma, especially in advanced lung adenocarcinoma." | 7.74 | NS-398 enhances the efficacy of gemcitabine against lung adenocarcinoma through up-regulation of p21WAF1 and p27KIP1 protein. ( Chen, XJ; Qu, X; Xiao, W; Zhou, SY, 2008) |
| "The aim of our study was to characterize the effects of two COX-2 selective inhibitors, NS-398 and nimesulide, on colorectal cancer cell proliferation, and to describe the molecular mechanisms involved." | 7.72 | Molecular mechanisms involved in the antiproliferative effect of two COX-2 inhibitors, nimesulide and NS-398, on colorectal cancer cell lines. ( Blottière, HM; Bonnet, C; Bouancheau, D; Broquet, A; Buecher, B; Denis, MG; Galmiche, JP; Heymann, MF; Jany, A, 2003) |
| "Gemcitabine is a chemotherapeutic drug widely used in the treatment of non-small cell lung carcinoma, especially in advanced lung adenocarcinoma." | 3.74 | NS-398 enhances the efficacy of gemcitabine against lung adenocarcinoma through up-regulation of p21WAF1 and p27KIP1 protein. ( Chen, XJ; Qu, X; Xiao, W; Zhou, SY, 2008) |
| "We investigated the primary adenoma cells and HT-29 cells in an attempt to know whether NaBT and two NSAIDs (aspirin and NS-398) could be used as effective adjuvant for reducing cell proliferation, and to explore the possible mechanisms therein involved." | 3.72 | [Effects of NaBT and NSAIDs on colorectal adenoma-carcinoma cells]. ( Gan, H; Ouyang, Q; Zhang, Z, 2003) |
| "The aim of our study was to characterize the effects of two COX-2 selective inhibitors, NS-398 and nimesulide, on colorectal cancer cell proliferation, and to describe the molecular mechanisms involved." | 3.72 | Molecular mechanisms involved in the antiproliferative effect of two COX-2 inhibitors, nimesulide and NS-398, on colorectal cancer cell lines. ( Blottière, HM; Bonnet, C; Bouancheau, D; Broquet, A; Buecher, B; Denis, MG; Galmiche, JP; Heymann, MF; Jany, A, 2003) |
| "Two esophageal adenocarcinoma cell lines (SEG-1 and BIC) and two esophageal squamous cell cancer lines (KYSE 150 and KYSE 410) were treated with rofecoxib at doses ranging from 8." | 3.72 | Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1). ( Jackson, BJ; McFadden, DW; Riggs, DR; Vona-Davis, L, 2004) |
| "Adenocarcinoma cells HT-29 were used to investigate whether butyrates and non-steroidal anti-inflammatory agents (NSAIDs, aspirin and NS-398) would be effective adjuvants for inducing apoptosis and to probe its possible mechanisms." | 3.71 | [The effects of butyrates and non-steroidal anti-inflammatory agents on HT-29 colonic carcinoma cells]. ( Gan, H; Ouyang, Q; Zhang, Z, 2002) |
| "The treatment of Barrett's esophagus is controversial." | 2.43 | [The clinical strategy for the Barrett's esophagus]. ( Goto, H; Kitabatake, S; Niwa, Y, 2005) |
| "Bone is the most common site for breast cancer spread." | 1.48 | The therapeutic effect of miR-125b is enhanced by the prostaglandin endoperoxide synthase 2/cyclooxygenase 2 blockade and hampers ETS1 in the context of the microenvironment of bone metastasis. ( Bendinelli, P; Desiderio, MA; Maroni, P; Matteucci, E, 2018) |
| "The incidence of oesophageal cancer (OC) has risen in recent decades, with survival rates remaining poor despite surgical treatment and adjuvant chemotherapy." | 1.34 | Cyclooxygenase-2 inhibitors demonstrate anti-proliferative effects in oesophageal cancer cells by prostaglandin E(2)-independent mechanisms. ( Deasy, BM; McKenna, SL; O'Donovan, TR; O'Sullivan, GC; O'Sullivan-Coyne, G, 2007) |
| "Human colon cancer Caco-2 cells were treated with either: placebo, IND (0." | 1.33 | Identification of specific genes and pathways involved in NSAIDs-induced apoptosis of human colon cancer cells. ( Chai, J; Huang, RH; Tarnawski, AS, 2006) |
| "Two human colorectal cancer cell lines, LS174T and HT29, were challenged with MMP inhibitor (doxycycline), selective COX-2 inhibitor (NS-398), or a combination of these agents to evaluate cancer cell proliferation and invasion." | 1.32 | Doxycycline inhibits cell proliferation and invasive potential: combination therapy with cyclooxygenase-2 inhibitor in human colorectal cancer cells. ( Dhar, DK; Fujii, T; Nagasue, N; Ono, T; Onoda, T; Yamanoi, A, 2004) |
| "Biopsies from nondysplastic Barrett's esophagus expressed increased gastrin mRNA levels compared with other biopsies." | 1.32 | Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis. ( Abdalla, SI; Fitzgerald, RC; Lao-Sirieix, P; Lovat, LB; Novelli, MR; Sanderson, IR, 2004) |
| "Ibuprofen was significantly more effective against human prostate cancer cells in vitro than the other tested nonprescription NSAIDs." | 1.31 | Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells. ( Andrews, J; Andrews, P; Djakiew, D; Krygier, S, 2002) |
| "To investigate the role of COX-2 in pancreatic cancer, we evaluated COX-2 protein expression in primary human pancreatic adenocarcinomas (n = 23) and matched normal adjacent tissue (n = 11) by immunoblot analysis." | 1.31 | Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. ( Barnard, DS; Billings, SD; Cheng, L; Crowell, PL; Heilman, DK; Lin, A; Marshall, MS; Marshall, SJ; Sweeney, CJ; Yip-Schneider, MT, 2000) |
| "Adenocarcinoma in Barrett's esophagus has been increasing in incidence at a rapid rate for more than two decades." | 1.31 | Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. ( Beer, DG; Cryer, B; Shewmake, K; Souza, RF; Spechler, SJ, 2000) |
| "NSAIDs similarly induce apoptosis in esophageal cancer cells, although the mechanisms of these effects remain to be defined." | 1.31 | Nonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase-1 expression. ( Chen, D; Fischer, SM; Lippman, SM; Lotan, R; Morris, JS; Shureiqi, I; Xu, X, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (6.06) | 18.2507 |
| 2000's | 27 (81.82) | 29.6817 |
| 2010's | 4 (12.12) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maroni, P | 1 |
| Bendinelli, P | 1 |
| Matteucci, E | 1 |
| Desiderio, MA | 1 |
| Huang, RY | 1 |
| Li, SS | 1 |
| Guo, HZ | 1 |
| Huang, Y | 1 |
| Zhang, X | 1 |
| Li, MY | 1 |
| Chen, GG | 1 |
| Zeng, X | 1 |
| Galamb, O | 1 |
| Spisák, S | 1 |
| Sipos, F | 1 |
| Tóth, K | 1 |
| Solymosi, N | 1 |
| Wichmann, B | 1 |
| Krenács, T | 1 |
| Valcz, G | 1 |
| Tulassay, Z | 1 |
| Molnár, B | 1 |
| Gu, KS | 1 |
| Chen, Y | 1 |
| Yao, M | 1 |
| Song, DH | 1 |
| Rana, B | 1 |
| Wolfe, MM | 1 |
| Andrews, J | 1 |
| Djakiew, D | 2 |
| Krygier, S | 2 |
| Andrews, P | 2 |
| Nithipatikom, K | 1 |
| Isbell, MA | 1 |
| Lindholm, PF | 1 |
| Kajdacsy-Balla, A | 1 |
| Kaul, S | 1 |
| Campell, WB | 1 |
| Zhang, Z | 3 |
| Ouyang, Q | 2 |
| Gan, H | 2 |
| Wen, B | 1 |
| Deutsch, E | 1 |
| Eschwege, P | 1 |
| De Crevoisier, R | 1 |
| Nasr, E | 1 |
| Eschwege, F | 1 |
| Bourhis, J | 1 |
| Buecher, B | 1 |
| Broquet, A | 1 |
| Bouancheau, D | 1 |
| Heymann, MF | 1 |
| Jany, A | 1 |
| Denis, MG | 1 |
| Bonnet, C | 1 |
| Galmiche, JP | 1 |
| Blottière, HM | 1 |
| Schmidt, CM | 1 |
| Wang, Y | 1 |
| Wiesenauer, C | 1 |
| Onoda, T | 1 |
| Ono, T | 1 |
| Dhar, DK | 1 |
| Yamanoi, A | 1 |
| Fujii, T | 1 |
| Nagasue, N | 1 |
| Vona-Davis, L | 1 |
| Riggs, DR | 1 |
| Jackson, BJ | 1 |
| McFadden, DW | 1 |
| Holzer, RG | 1 |
| Ryan, RE | 1 |
| Tommack, M | 1 |
| Schlekeway, E | 1 |
| Jorcyk, CL | 1 |
| Abdalla, SI | 1 |
| Lao-Sirieix, P | 1 |
| Novelli, MR | 1 |
| Lovat, LB | 1 |
| Sanderson, IR | 1 |
| Fitzgerald, RC | 1 |
| Kitabatake, S | 1 |
| Niwa, Y | 1 |
| Goto, H | 1 |
| Kudryavtsev, IA | 1 |
| Gudkova, MV | 1 |
| Pavlova, OM | 1 |
| Oreshkin, AE | 1 |
| Myasishcheva, NV | 1 |
| Huang, RH | 1 |
| Chai, J | 1 |
| Tarnawski, AS | 2 |
| Takehara, H | 1 |
| Iwamoto, J | 2 |
| Mizokami, Y | 1 |
| Takahashi, K | 1 |
| Ootubo, T | 1 |
| Miura, S | 1 |
| Narasaka, T | 1 |
| Takeyama, H | 1 |
| Omata, T | 1 |
| Shimokobe, K | 1 |
| Ito, M | 1 |
| Matsuoka, T | 1 |
| Baguma-Nibasheka, M | 1 |
| Barclay, C | 1 |
| Li, AW | 1 |
| Geldenhuys, L | 1 |
| Porter, GA | 1 |
| Blay, J | 1 |
| Casson, AG | 1 |
| Murphy, PR | 1 |
| Deasy, BM | 1 |
| O'Sullivan-Coyne, G | 1 |
| O'Donovan, TR | 1 |
| McKenna, SL | 1 |
| O'Sullivan, GC | 1 |
| Chen, XJ | 1 |
| Xiao, W | 1 |
| Qu, X | 1 |
| Zhou, SY | 1 |
| Ogunwobi, OO | 1 |
| Beales, IL | 1 |
| Sawaoka, H | 1 |
| Kawano, S | 1 |
| Tsuji, S | 1 |
| Tsujii, M | 1 |
| Murata, H | 1 |
| Hori, M | 1 |
| Molina, MA | 1 |
| Sitja-Arnau, M | 1 |
| Lemoine, MG | 1 |
| Frazier, ML | 1 |
| Sinicrope, FA | 1 |
| Yip-Schneider, MT | 1 |
| Barnard, DS | 1 |
| Billings, SD | 1 |
| Cheng, L | 1 |
| Heilman, DK | 1 |
| Lin, A | 1 |
| Marshall, SJ | 1 |
| Crowell, PL | 1 |
| Marshall, MS | 1 |
| Sweeney, CJ | 1 |
| Souza, RF | 1 |
| Shewmake, K | 1 |
| Beer, DG | 1 |
| Cryer, B | 1 |
| Spechler, SJ | 1 |
| Lim, JW | 1 |
| Kim, H | 1 |
| Kim, KH | 1 |
| Shureiqi, I | 1 |
| Xu, X | 1 |
| Chen, D | 1 |
| Lotan, R | 1 |
| Morris, JS | 1 |
| Fischer, SM | 1 |
| Lippman, SM | 1 |
| DuBois, RN | 1 |
| Husain, SS | 1 |
| Szabo, IL | 1 |
| Pai, R | 1 |
| Soreghan, B | 1 |
| Jones, MK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Double Blind, Placebo Controlled Trial of Doxycycline in Lymphangioleiomyomatosis.[NCT00989742] | Phase 4 | 24 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide and Adenocarcinoma
| Article | Year |
|---|---|
[The clinical strategy for the Barrett's esophagus].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Ba | 2005 |
32 other studies available for n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide and Adenocarcinoma
| Article | Year |
|---|---|
The therapeutic effect of miR-125b is enhanced by the prostaglandin endoperoxide synthase 2/cyclooxygenase 2 blockade and hampers ETS1 in the context of the microenvironment of bone metastasis.
Topics: Adenocarcinoma; Animals; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cyclooxygenase 2; Femal | 2018 |
Thromboxane A2 exerts promoting effects on cell proliferation through mediating cyclooxygenase-2 signal in lung adenocarcinoma cells.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenocarcinoma; Adenocarcinoma o | 2014 |
Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor.
Topics: Adenocarcinoma; Adenoma; Cluster Analysis; Colon; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; | 2010 |
Mechanism of P-glycoprotein expression in the SGC7901 human gastric adenocarcinoma cell line induced by cyclooxygenase-2.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; A | 2012 |
COX-2 selective inhibition reverses the trophic properties of gastrin in colorectal cancer.
Topics: Adenocarcinoma; Animals; Cell Division; Colonic Neoplasms; Cyclin D1; Cyclooxygenase 2; Cyclooxygena | 2002 |
Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells.
Topics: Acetaminophen; Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Divis | 2002 |
Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion.
Topics: 6-Ketoprostaglandin F1 alpha; Adenocarcinoma; Arachidonic Acid; Cyclooxygenase 1; Cyclooxygenase 2; | 2002 |
[Effects of NaBT and NSAIDs on colorectal adenoma-carcinoma cells].
Topics: Adenocarcinoma; Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Butyrates; Cel | 2003 |
Cyclooxygenase-2 inhibitor NS398 enhances antitumor effect of irradiation on hormone refractory human prostate carcinoma cells.
Topics: Adenocarcinoma; Cell Division; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cycloox | 2003 |
Molecular mechanisms involved in the antiproliferative effect of two COX-2 inhibitors, nimesulide and NS-398, on colorectal cancer cell lines.
Topics: Adenocarcinoma; Apoptosis; Blotting, Western; Cell Cycle Proteins; Cell Division; Colorectal Neoplas | 2003 |
Novel combination of cyclooxygenase-2 and MEK inhibitors in human hepatocellular carcinoma provides a synergistic increase in apoptosis.
Topics: Adenocarcinoma; Apoptosis; Butadienes; Carcinoma, Hepatocellular; Cell Cycle; Cell Division; Cell Li | 2003 |
Doxycycline inhibits cell proliferation and invasive potential: combination therapy with cyclooxygenase-2 inhibitor in human colorectal cancer cells.
Topics: Adenocarcinoma; Anti-Bacterial Agents; Apoptosis; Blotting, Western; Cell Division; Cell Line, Tumor | 2004 |
Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1).
Topics: Adenocarcinoma; Apoptosis; Cell Division; Cell Line, Tumor; Cyclooxygenase 1; Cyclooxygenase 2; Cycl | 2004 |
Oncostatin M stimulates the detachment of a reservoir of invasive mammary carcinoma cells: role of cyclooxygenase-2.
Topics: Adenocarcinoma; Animals; Cell Adhesion; Cell Line, Tumor; Collagen; Contraindications; Cyclooxygenas | 2004 |
Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Barrett Esophagus; Benzodiazepines; Blot | 2004 |
Lipoxygenase pathway of arachidonic acid metabolism in growth control of tumor cells of different type.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Adenocarcinoma; Arachidonate Lipoxygenases; Arachidonic | 2005 |
Identification of specific genes and pathways involved in NSAIDs-induced apoptosis of human colon cancer cells.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Caco-2 Cells; Caspases; Colonic | 2006 |
Involvement of cyclooxygenase-2--prostaglandin E2 pathway in interleukin-8 production in gastric cancer cells.
Topics: Adenocarcinoma; Arachidonic Acid; Biphenyl Compounds; Cell Line, Tumor; Cyclic AMP; Cyclooxygenase 2 | 2006 |
Selective cyclooxygenase-2 inhibition suppresses basic fibroblast growth factor expression in human esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Cyclooxygenase 2 | 2007 |
Cyclooxygenase-2 inhibitors demonstrate anti-proliferative effects in oesophageal cancer cells by prostaglandin E(2)-independent mechanisms.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; C | 2007 |
NS-398 enhances the efficacy of gemcitabine against lung adenocarcinoma through up-regulation of p21WAF1 and p27KIP1 protein.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cyclin- | 2008 |
Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells.
Topics: Adenocarcinoma; Analysis of Variance; Animals; Apoptosis; Barrett Esophagus; Caspase 3; Cell Divisio | 2008 |
Effects of NSAIDs on proliferation of gastric cancer cells in vitro: possible implication of cyclooxygenase-2 in cancer development.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Blotting, Northern; Blotting, We | 1998 |
Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Cell Division; Cyclooxygenase 1; Cyclooxyge | 1999 |
Cyclooxygenase-2 expression in human pancreatic adenocarcinomas.
Topics: Adenocarcinoma; Animals; Cell Line, Transformed; Codon; Cricetinae; Cyclooxygenase 2; Cyclooxygenase | 2000 |
Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Barrett Esophagus; Cell Division | 2000 |
Nuclear factor-kappaB regulates cyclooxygenase-2 expression and cell proliferation in human gastric cancer cells.
Topics: 6-Ketoprostaglandin F1 alpha; Adenocarcinoma; Cell Division; Cyclooxygenase 2; Cyclooxygenase 2 Inhi | 2001 |
Nonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase-1 expression.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Arachidonate 15-Lipoxygenase; Ca | 2001 |
Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apopt | 2001 |
MAPK (ERK2) kinase--a key target for NSAIDs-induced inhibition of gastric cancer cell proliferation and growth.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cell Division; Cyclooxygenase In | 2001 |
Dihydrotestosterone (DHT) modulates the ability of NSAIDs to induce apoptosis of prostate cancer cells.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cyclooxygenase 2; Cyclooxygenase | 2002 |
[The effects of butyrates and non-steroidal anti-inflammatory agents on HT-29 colonic carcinoma cells].
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Butyrates; Colonic Neop | 2002 |